Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3
The experimentally established mechanism targets of Epinephrine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 8/20 | 0.84 |
| ▸ | ADRB1 known ✓ | P08588 | 7/20 | 0.84 |
| ▸ | ADRB3 known ✓ | P13945 | 5/20 | 0.84 |
| ▸ | ADRA2A known ✓ | P08913 | 4/20 | 0.84 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.84 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.84 |
| ▸ | ADRA1D known ✓ | P25100 | 4/20 | 0.84 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.84 |
| ▸ | ADRA1B known ✓ | P35368 | 3/20 | 0.84 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.84 |
| ▸ | MAPT | P10636 | 9/20 | 0.84 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.84 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.84 |
| ▸ | TSHR | P16473 | 5/20 | 0.84 |
| ▸ | MEN1 | O00255 | 4/20 | 0.84 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.84 |
| ▸ | RECQL | P46063 | 4/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.84 |
| ▸ | APEX1 | P27695 | 3/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epinephrine SCHEMBL2691388 | 0.92 | TDP1 (0.93) | TDP1MAPTKDM4EADRB2ADRB1 | |
| [11C]Epinephrine SCHEMBL29374823 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Racepinephrine SCHEMBL29396039 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Epinephrine SCHEMBL29353423 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Racepinephrine SCHEMBL11631789 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Epinephrine SCHEMBL2837188 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| L-Adrenaline SCHEMBL11647 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Racepinephrine SCHEMBL3815 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| Racepinephrine SCHEMBL20493843 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 | |
| [11C]Epinephrine SCHEMBL29371663 | 0.92 | KDM4E (1.00) | TDP1MAPTKDM4EADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240120053-A1 | 5-HT RECEPTOR AGONIST TITRATION | DIAMOND THERAPEUTICS INC. (CA) | 2024-04-11 | — | — | US | disclosed |
| WO-2024047497-A1 | TREATMENTS FOR PRURIGO NODULARIS | Galderma Holding SA (CH) | 2024-03-07 | — | — | WO | disclosed |
| US-20240074996-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION | KETO INNOVATIONS, LLC (US) | 2024-03-07 | — | — | US | disclosed |
| US-20230364442-A1 | DEVICE AND METHOD FOR APPLYING PHOTOBIOMODULATION | G LIFE (FR) | 2023-11-16 | — | — | US | disclosed |
| US-20230364043-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | KETO INNOVATIONS, LLC (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4221828-A1 | DEVICE AND METHOD FOR APPLYING PHOTOBIOMODULATION | G Life (FR) | 2023-08-09 | — | — | EP | disclosed |
| US-20230149329-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | KETO INNOVATIONS, LLC (US) | 2023-05-18 | — | — | US | disclosed |
| WO-2023046911-A1 | METHODS FOR STIMULUS-SENSITIVE ACTUATION OF NANOMEMBRANES AND DEVICES THEREFORE | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2023-03-30 | — | — | WO | disclosed |
| WO-2022069755-A1 | DEVICE AND METHOD FOR APPLYING PHOTOBIOMODULATION | G LIFE (FR) | 2022-04-07 | — | — | WO | disclosed |
| CN-104304104-B | Method for preparing monomer oyster fries by utilizing vertical growth characteristics of oysters | 中国科学院南海海洋研究所 | 2017-01-25 | — | — | CN | disclosed |
| WO-2002004612-A2 | DRUG METABOLIZING ENZYMES | INCYTE GENOMICS, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| EP-1007068-A4 | PROCESS FOR PREPARING SYNTHETIC SOIL-EXTRACT MATERIALS AND MEDICAMENTS BASED THEREON | LAUB BIOCHEMICALS CORP (US) | 2001-04-25 | — | — | EP | disclosed |
| EP-1007068-A1 | PROCESS FOR PREPARING SYNTHETIC SOIL-EXTRACT MATERIALS AND MEDICAMENTS BASED THEREON | Laub Biochemicals Corporation (US) | 2000-06-14 | — | — | EP | disclosed |
| WO-1998034629-A1 | PROCESS FOR PREPARING SYNTHETIC SOIL-EXTRACT MATERIALS AND MEDICAMENTS BASED THEREON | LAUB BIOCHEMICALS CORPORATION (US) | 1998-08-13 | — | — | WO | disclosed |
| EP-0848059-A1 | Mammalian ICYP (Iodocyanopindolol) receptor and its applications | Vetigen (FR) | 1998-06-17 | — | — | EP | disclosed |
| EP-0669940-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | THE UNIVERSITY OF TORONTO INNOVATIONS FOUNDATION (CA) | 1995-09-06 | — | — | EP | disclosed |
| WO-1994011399-A1 | SPECIFICALLY CROSSLINKED HEMOGLOBIN WITH FREE FUNCTIONALITY | KLUGER RONALD (CA) | 1994-05-26 | — | — | WO | disclosed |
| EP-0502987-A1 | ACYLATED BRADYKININ ANTAGONISTS AND USES THEREFOR. | UNIV BOSTON (US) | 1992-09-16 | — | — | EP | disclosed |
| US-4704403-A | HYPOTENSIVE, ANTIARRHYTHMIA | BREMANIS GUNAR A (SU) | 1987-11-03 | — | — | US | disclosed |
| US-4208420-A | ANALGESICS, VASOREGULATOR, SYMPATHETIC STIMULANTS | LABORATOIRES JACQUES LOGEAIS (FR) | 1980-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240074996-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR TREATING METABOLIC DYSFUNCTION | ECHS1, CPT1B, CPT2 | ADRB2 3190/4885ADRB1 3093/4885ADRB3 2203/4885 |
| US-20230149329-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | CPT1B, ECHS1, CPT2 | ADRB2 3261/4885ADRB1 3064/4885ADRB3 2097/4885 |
| US-20230364043-A1 | C5 KETONE COMPOSITIONS AND RELATED METHODS FOR THERAPEUTIC AND PERFORMANCE SUPPLEMENTATION | CPT1B, ECHS1, CPT2 | ADRB2 3261/4885ADRB1 3064/4885ADRB3 2097/4885 |
| US-20240120053-A1 | 5-HT RECEPTOR AGONIST TITRATION | HTR1A, HTR3A, HTR5A | ADRB2 145/4885ADRB1 139/4885ADRB3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.